Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 1/20 | 0.34 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.34 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TMEM97 | Q5BJF2 | 4/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.33 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.31 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.31 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25427006 | 0.89 | KMT2A (0.39) | MEN1KMT2AKDM4ETMEM97SIGMAR1 | |
| SCHEMBL25331905 | 0.85 | CHRM2 (0.47) | CHRM2KDM4ETMEM97SIGMAR1PAOX | |
| SCHEMBL8927622 | 0.83 | PAOX (0.50) | KDM4EPAOXMTNR1AMTNR1B | |
| SCHEMBL25204410 | 0.81 | MAPT (0.35) | MEN1KMT2AKDM4ETMEM97SIGMAR1 | |
| SCHEMBL1111100 | 0.80 | CHRM2 (0.45) | CHRM2TMEM97SIGMAR1PAOXDNM1 | |
| SCHEMBL21017754 | 0.79 | POLB (0.37) | MEN1KMT2ACHRM2KDM4E | |
| SCHEMBL31496692 | 0.79 | CHRM2 (0.54) | CHRM2KDM4ETMEM97SIGMAR1PAOX | |
| SCHEMBL11709883 | 0.78 | KDM5A (0.42) | MEN1KMT2AKDM4ETMEM97SIGMAR1 | |
| SCHEMBL15542027 | 0.78 | CA12 (0.37) | MEN1KMT2AKDM4EPAOXCYP2C19 | |
| SCHEMBL2236238 | 0.78 | CA12 (0.37) | MEN1KMT2AKDM4EPAOXCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024129600-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR (GNRHR) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| WO-2023147328-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION WITH HYDOLYSABLE MALEIMIDE LINKERS AND METHODS THEREOF | GENENTECH, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20220153751-A1 | BIFUNCTIONAL COMPOUNDS | BIOTHERYX, INC. (US) | 2022-05-19 | — | — | US | disclosed |
| US-11236103-B2 | Bifunctional compounds | BIOTHERYX, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| EP-3830093-A1 | BIFUNCTIONAL COMPOUNDS AS CDK MODULATORS | Biotheryx, Inc. (US) | 2021-06-09 | — | — | EP | disclosed |
| US-20200048277-A1 | BIFUNCTIONAL COMPOUNDS | BIOTHERYX, INC. | 2020-02-13 | — | — | US | disclosed |
| WO-2020023782-A1 | BIFUNCTIONAL COMPOUNDS AS CDK MODULATORS | BIOTHERYX, INC. (US) | 2020-01-30 | — | — | WO | disclosed |
| US-20180028674-A1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2018-02-01 | — | — | US | disclosed |
| US-RE46605-E1 | Fatty acid niacin conjugates and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-RE46608-E1 | Fatty acid niacin conjugates and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| WO-2011044141-A1 | FATTY ACID FIBRATE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2011-04-14 | — | — | WO | disclosed |
| WO-2011044136-A1 | FATTY ACID ACIPIMOX DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2011-04-14 | — | — | WO | disclosed |
| US-20110082210-A1 | FATTY ACID FIBRATE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2011-04-07 | — | — | US | disclosed |
| US-20110082156-A1 | FATTY ACID ACIPIMOX DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2011-04-07 | — | — | US | disclosed |
| US-20110082192-A1 | LIPOIC ACID ACYLATED SALICYLATE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2011-04-07 | — | — | US | disclosed |
| WO-2011028689-A1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2011-03-10 | — | — | WO | disclosed |
| US-20110053990-A1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2011-03-03 | — | — | US | disclosed |
| US-20100184730-A1 | Fatty Acid Acylated Salicylates and Their Uses | CATABASIS PHARMACEUTICALS, INC. | 2010-07-22 | — | — | US | disclosed |
| US-20070191372-A1 | Dna-targeted benzotriazine 1,4-dioxides and their use in cancer therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2007-08-16 | — | — | US | disclosed |
| WO-2004026846-A1 | DNA-TARGETED BENZOTRIAZINE 1,4-DIOXIDES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053990-A1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | NAMPT, NAPRT, FASN | CARM1 3669/4885PRMT6 3622/4885PRMT8 4212/4885 |
| US-20200048277-A1 | BIFUNCTIONAL COMPOUNDS | CDK2, CDK6, CDK5 | CARM1 1295/4885PRMT6 324/4885PRMT8 504/4885 |
| US-11236103-B2 | Bifunctional compounds | CDK2, CDK6, CDK5 | CARM1 1295/4885PRMT6 324/4885PRMT8 504/4885 |
| US-20070191372-A1 | Dna-targeted benzotriazine 1,4-dioxides and their use in cancer therapy | HIF1AN, HIF1A, HYOU1 | CARM1 480/4885PRMT6 3298/4885PRMT8 2997/4885 |
| US-20110082210-A1 | FATTY ACID FIBRATE DERIVATIVES AND THEIR USES | FABP1, PPARA, FABP4 | CARM1 2944/4885PRMT6 3084/4885PRMT8 3787/4885 |
| US-20110082192-A1 | LIPOIC ACID ACYLATED SALICYLATE DERIVATIVES AND THEIR USES | ACACA, ACAT2, ACACB | CARM1 3608/4885PRMT6 3658/4885PRMT8 4132/4885 |
| US-20110082156-A1 | FATTY ACID ACIPIMOX DERIVATIVES AND THEIR USES | ACOX3, ACOX1, PAOX | CARM1 2728/4885PRMT6 2405/4885PRMT8 3555/4885 |
| US-20220153751-A1 | BIFUNCTIONAL COMPOUNDS | CDK2, CDK6, CDK5 | CARM1 1295/4885PRMT6 324/4885PRMT8 504/4885 |
| US-20100184730-A1 | Fatty Acid Acylated Salicylates and Their Uses | FADS1, FASN, ALOX5 | CARM1 3907/4885PRMT6 4609/4885PRMT8 4676/4885 |
| US-20180028674-A1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | NAMPT, NAPRT, FASN | CARM1 3669/4885PRMT6 3622/4885PRMT8 4212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.